Bureau Veritas (GB:0MH1)
LSE:0MH1
0MH1 Stock Chart & Stats
€26.95
-€0.24(-0.83%)
At close: 4:00 PM EST
€26.95
-€0.24(-0.83%)
Day’s Range― - ―
52-Week Range€25.32 - €30.44
Previous CloseN/A
Volume477.56K
Average Volume (3M)546.95K
Market Cap
€11.97B
Enterprise Value€14.04B
Total Cash (Recent Filing)€1.37B
Total Debt (Recent Filing)€3.43B
Price to Earnings (P/E)20.6
Beta1.00
Next Earnings
Jul 23, 2026EPS Estimate
0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.80
Shares Outstanding453,871,520
10 Day Avg. Volume339,683
30 Day Avg. Volume546,951
Financial Highlights & Ratios
PEG Ratio4.33
Price to Book (P/B)7.08
Price to Sales (P/S)1.87
P/FCF Ratio14.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€32.61Price Target Upside21.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)1.56
Revenue Forecast (FY)€6.79B
Bulls Say, Bears Say
Bulls Say
Recurring, Diversified Revenue ModelBureau Veritas's core TIC fee-based model—testing, on-site inspections and multi-year certification cycles—generates recurring, contract-driven revenue. Cross-selling across industrial, maritime, consumer and infrastructure clients and regulatory-driven demand provide durable cash visibility and lower cyclicality over months.
Strong Free Cash Flow GenerationConsistent FCF (~€820M in 2025) and robust operating cash (~€967M) show the company's ability to convert profits into usable cash. This sustained cash generation supports capital allocation for reinvestment, dividends and debt service, enhancing financial flexibility over the next several quarters.
Durable Operating ProfitabilityHealthy operating margin (~14%) and stable net margins (~8–9%) indicate structural profitability in the service-led TIC business. These margins provide a buffer for investment and cyclical revenue swings, supporting sustained earnings power and the ability to fund strategic priorities over the medium term.
Bears Say
Elevated And Rising LeverageDebt growth to ~€3.43B and a jump in debt-to-equity to ~2.01x materially raise financial risk. Higher leverage limits flexibility, increases refinancing and interest-rate exposure, and constrains the company's ability to pursue opportunistic investments or absorb operational shocks over the coming quarters.
Declining Equity BaseA shrinking equity base amplifies leverage metrics and reduces loss-absorbing capacity. With falling shareholders' equity alongside rising debt, solvency measures weaken and the company faces higher marginal financing costs and less buffer for adverse scenarios in the medium term.
Gross-margin Inconsistency And Cash-conversion DragVolatility in gross margin suggests changes in business mix or cost recognition that reduce confidence in margin trends. Coupled with sub-0.5 cash coverage of operating profit, this points to working-capital or conversion inefficiencies that could pressure free cash flow reliability if trends persist.
Bureau Veritas News
0MH1 FAQ
What was Bureau Veritas’s price range in the past 12 months?
Bureau Veritas lowest share price was €25.32 and its highest was €30.44 in the past 12 months.
What is Bureau Veritas’s market cap?
Bureau Veritas’s market cap is €11.97B.
When is Bureau Veritas’s upcoming earnings report date?
Bureau Veritas’s upcoming earnings report date is Jul 23, 2026 which is in 103 days.
How were Bureau Veritas’s earnings last quarter?
Bureau Veritas released its earnings results on Feb 25, 2026. The company reported €0.804 earnings per share for the quarter, the consensus estimate of €0.804 by €0.
Is Bureau Veritas overvalued?
According to Wall Street analysts Bureau Veritas’s price is currently Undervalued.
Does Bureau Veritas pay dividends?
Bureau Veritas does not currently pay dividends.
What is Bureau Veritas’s EPS estimate?
Bureau Veritas’s EPS estimate is 0.69.
How many shares outstanding does Bureau Veritas have?
Bureau Veritas has 453,871,520 shares outstanding.
What happened to Bureau Veritas’s price movement after its last earnings report?
Bureau Veritas reported an EPS of €0.804 in its last earnings report, expectations of €0.804. Following the earnings report the stock price went up 1.303%.
Which hedge fund is a major shareholder of Bureau Veritas?
Currently, no hedge funds are holding shares in GB:0MH1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bureau Veritas
Bureau Veritas SA provides laboratory testing, inspection, and certification services. It operates through six segments: Marine & Offshore; Agri-Food & Commodities; Industry; Buildings & Infrastructure; Certification; and Consumer Products. The company engages in the inspecting, analyzing, auditing, and certifying the products, assets, and management systems of its customers in relation to regulatory benchmarks or volunteers, as well as issues compliance reports. It also provides laboratory and on-site testing services for manufacturing and process industries; inspection services for products, services, assets, and installations, as well as designed to control quality, verify quantity, and meet regulatory requirements; and certification services for management systems, products, and people. The company serves automotive and transportation, building and infrastructure, chemicals, commodities and agriculture, consumer products and retail, food, marine and offshore, oil and gas, and power and utilities industries, as well as financial services and public sectors. It operates in approximately 140 countries through a network of 1,600 offices and laboratories. Bureau Veritas SA was founded in 1828 and is based in Neuilly-sur-Seine, France.
0MH1 Stock 12 Month Forecast
Average Price Target
€32.61
▲(21.00% Upside)
Technical Analysis
bioMerieux
―
Eurofins Scientific
―
ID LOGISTICS
―
Sartorius Stedim Biotech
―
SPIE SA
―
Options Prices
Currently, No data available
---